Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuuli Ranki

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Viruses|October 14, 2011
Serotype chimeric human adenoviruses for cancer gene therapyTuuli Ranki, Akseli Hemminki
International Journal of Cancer|February 23, 2007
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancerTuuli Ranki, Merja Särkioja, Tanja Hakkarainen, et al.
International Journal of Cancer|June 12, 2016
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma modelLukasz Kuryk, Elina Haavisto, Mariangela Garofalo, et al.
Cancer|September 2, 2006
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancerMerja Sarkioja, Anna Kanerva, Jarmo Salo, et al.
Molecular Cancer Therapeutics|October 17, 2007
Treatment of metastatic renal cancer with capsid-modified oncolytic adenovirusesKilian Guse, Tuuli Ranki, Martti Ala-Opas, et al.
Plos One|August 11, 2017
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatmentLukasz Kuryk, Lotta Vassilev, Tuuli Ranki, et al.
Future Oncology (London, England)|October 13, 2023
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, FinlandJohanna Vikkula, Kristiina Uusi-Rauva, Tuuli Ranki, et al.
Acta Dermato-Venereologica|March 31, 2022
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in FinlandSamuli Tuominen, Liisa Ukkola-Vuoti, Pilvi Riihilä, et al.
The Journal of Gene Medicine|December 7, 2006
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicityAnna Kanerva, Mari Raki, Tuuli Ranki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancerLotta Kangasniemi, Tuula Kiviluoto, Anna Kanerva, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Viruses|October 14, 2011
Serotype chimeric human adenoviruses for cancer gene therapyTuuli Ranki, Akseli Hemminki
International Journal of Cancer|February 23, 2007
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancerTuuli Ranki, Merja Särkioja, Tanja Hakkarainen, et al.
International Journal of Cancer|June 12, 2016
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma modelLukasz Kuryk, Elina Haavisto, Mariangela Garofalo, et al.
Cancer|September 2, 2006
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancerMerja Sarkioja, Anna Kanerva, Jarmo Salo, et al.
Molecular Cancer Therapeutics|October 17, 2007
Treatment of metastatic renal cancer with capsid-modified oncolytic adenovirusesKilian Guse, Tuuli Ranki, Martti Ala-Opas, et al.
Plos One|August 11, 2017
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatmentLukasz Kuryk, Lotta Vassilev, Tuuli Ranki, et al.
Future Oncology (London, England)|October 13, 2023
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, FinlandJohanna Vikkula, Kristiina Uusi-Rauva, Tuuli Ranki, et al.
Acta Dermato-Venereologica|March 31, 2022
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in FinlandSamuli Tuominen, Liisa Ukkola-Vuoti, Pilvi Riihilä, et al.
The Journal of Gene Medicine|December 7, 2006
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicityAnna Kanerva, Mari Raki, Tuuli Ranki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancerLotta Kangasniemi, Tuula Kiviluoto, Anna Kanerva, et al.
Pageof 2